At a glance
- Originator CeNeS Pharmaceuticals
- Class Guanidines; Sulfhydryl compounds
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer pain; Neuropathic pain
Most Recent Events
- 31 Mar 2010 Discontinued - Phase-II for Cancer pain in Europe (IV)
- 31 Mar 2010 Discontinued - Phase-II for Neuropathic pain in Europe (IV)
- 31 Mar 2010 Discontinued - Preclinical for Neuropathic pain in United Kingdom (Transdermal)